Borosilicate Glass Composition for Pharmaceutical Containers

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Borosilicate glass for pharmaceutical containers faces challenges in maintaining chemical durability and hydrolytic resistance, especially after thermal treatments, due to the evaporation of B2O3 or Na2O, leading to the formation of heterogeneous layers and the generation of insoluble precipitates, which affect the stability of aqueous-based medicaments.

Innovation Solution

A borosilicate glass composition with a molar ratio of (Na2O + K2O + Li2O - Al2O3)/B2O3 between 0.315 and 0.350, excluding BaO, and with specific ratios of SiO2, Al2O3, and B2O3, is developed to enhance chemical durability and hydrolytic resistance, reducing the evaporation of alkali metal oxides and maintaining stability during thermal treatments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If B2O3 or Na2O is used in borosilicate glass for pharmaceutical containers, then the glass can be processed by local heating with a burner, but B2O3 or Na2O evaporates during heating and condenses on the inner surface to form a heterogeneous layer, lowering chemical durability and hydrolytic resistance

Engineering Contradiction:
Improveprocessability by local heatingVSAvoidchemical durability and hydrolytic resistance
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The invention changes the compositional parameters of the glass by strictly controlling the ratio of (Na2O+K2O+Li2O-Al2O3)/B2O3 to be 0.315-0.350 and setting SiO2/B2O3/(Na2O+K2O+Li2O) < 1.6, which prevents excessive evaporation of B2O3 or Na2O during local heating while maintaining processability

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite glass system combining multiple oxide components (SiO2, B2O3, Al2O3, and controlled amounts of Na2O, K2O, Li2O, CaO, MgO) where each component plays a specific role in balancing processability and chemical durability, with the synergistic effect preventing heterogeneous layer formation

Inventive Principle:
Principle #40Composite materials

2Reliability

If the amount of K2O is increased to improve hydrolytic resistance, then hydrolytic resistance improves, but K2O is easily evaporated during burner heating, still causing formation of heterogeneous layer and elution of B2O3 or Na2O

Engineering Contradiction:
Improvehydrolytic resistanceVSAvoidevaporation of K2O, B2O3, or Na2O
Core Design Contradiction:
ReliabilityVSLoss of substance

Solution Approach 1:

The invention changes the compositional parameters by setting specific ranges for K2O content (0.1-5.0 mol%) and more importantly controlling the ratio SiO2/B2O3/(Na2O+K2O+Li2O) to be less than 1.6, which balances the volatility of alkali metal oxides with the network structure stability, preventing excessive evaporation while maintaining hydrolytic resistance

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention introduces B2O3 as an intermediary component that forms a stable network structure with SiO2 and Al2O3, which acts as a barrier to reduce the evaporation rate of K2O and other alkali metal oxides during heating, thereby preventing heterogeneous layer formation while maintaining hydrolytic resistance

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If BaO is included in the glass composition, then the glass can achieve certain properties, but barium-feldspar crystals precipitate during glass melting reducing productivity, and Ba ions react with sulfate ions in aqueous-based medicament to generate insoluble precipitate

Engineering Contradiction:
Improvechemical stabilityVSAvoidproduction efficiency
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The invention extracts BaO from the glass composition entirely, replacing it with a combination of other oxide components (particularly B2O3, Al2O3, and controlled amounts of CaO and MgO) that can achieve the desired chemical stability without causing crystal precipitation or harmful reactions with medicament components

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the compositional parameters by setting CaO content to 0-0.5 mol% and MgO content to 0-2.0 mol%, and controlling the ratio (Na2O+K2O+Li2O-Al2O3)/B2O3 to be 0.315-0.350, which achieves chemical stability through a different compositional pathway that avoids the problems associated with BaO

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This composition effectively prevents the formation of heterogeneous layers, reduces the generation of flakes, and maintains excellent chemical durability and hydrolytic resistance, even after thermal treatments, ensuring the stability and integrity of the glass container for pharmaceutical use.

Implementation Method 1

At the time of performing the heating with a burner, B2O3 or Na2O in the glass is evaporated and condensed on an inner surface of a pharmaceutical container

Methodology Applied
Scientific EffectEvaporation: Evaporation

Implementation Method 2

Chemical durability and hydrolytic resistance are high so as not to contaminate an aqueous-based medicament present in the container

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Data Source

PatentEP3326979B1Borosilicate glass for pharmaceutical container
Publication Date: 2022.12.14 NIPPON ELECTRIC GLASS CO LTD
  • EP3326979B1 patent drawingFigure 1
  • EP3326979B1 patent drawing

AI summary

To provide a borosilicate glass for a pharmaceutical container which does not include BaO, has excellent chemical durability and hydrolytic resistance, and in which excellent chemical durability and hydrolytic resistance may be maintained even after various thermal treatments at the time of converting process. There is provided a borosilicate glass for a pharmaceutical container including SiO2, Al2O3, B2O3, and R2O (R is one or more kinds selected from Li, Na, and K) as essential components, in which a content of CaO is equal to or greater than 0 and smaller than 0.5 mol%, a value of (Na2O + K2O + Li2O - Al2O3)/B2O3 is 0.315 to 0.350 in terms of a molar ratio, and BaO is not substantially included.